Company Overview

VBL Therapeutics is using its unique scientific platforms and drug development capabilities to fight psoriasis, rheumatoid arthritis and other serious chronic immune-inflammatory diseases, as well as cancer. Immune-inflammatory diseases and cancer are sometimes life-threatening diseases inadequately addressed by current therapies, and through its two technology platforms, VBL is developing programs to treat these serious diseases.

VBL Therapeutics pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201, the lead candidate from this program, has entered a Phase 2 clinical trial in patients with psoriasis, a disease that affects an estimated 125 million people worldwide. Preclinical studies indicate that VB-201 has significant potential to treat inflammation in other chronic diseases including rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and atherosclerosis.

VBL Therapeutics’ proprietary award-winning Vascular Targeting System (VTS™) technology platform has yielded VB-111, the first dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) for cancer, a leading cause of death worldwide. VB-111 has successfully completed Phase 1/2 single dose clinical trials in cancer patients, and is expected to enter Phase 2 clinical trials in 2010.

VBL Therapeutics’ primary focus is advancing our lead immuno-inflammatory and cancer therapies; however, our core technologies have potential application in other indications, which we are also pursuing opportunistically. VBL has 55 granted patents and more than 115 patents pending.

The company was founded in 2000 and is based in Tel Aviv, Israel.